Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Water and electrolyte homeostasis brings balance to physiology.

Pollock JS, Ryan MJ, Samson WK, Brooks DP.

Am J Physiol Regul Integr Comp Physiol. 2014 Sep 1;307(5):R481-3. doi: 10.1152/ajpregu.00246.2014. Epub 2014 Jul 16. Review.

2.

Comparison of non-digitalis binding properties of digoxin-specific Fabs using direct binding methods.

Pullen MA, Harpel MR, Danoff TM, Brooks DP.

J Immunol Methods. 2008 Jul 31;336(2):235-41. doi: 10.1016/j.jim.2008.05.005. Epub 2008 Jun 4.

PMID:
18555269
3.

N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part I.

Thorneloe KS, Sulpizio AC, Lin Z, Figueroa DJ, Clouse AK, McCafferty GP, Chendrimada TP, Lashinger ES, Gordon E, Evans L, Misajet BA, Demarini DJ, Nation JH, Casillas LN, Marquis RW, Votta BJ, Sheardown SA, Xu X, Brooks DP, Laping NJ, Westfall TD.

J Pharmacol Exp Ther. 2008 Aug;326(2):432-42. doi: 10.1124/jpet.108.139295. Epub 2008 May 22. Erratum in: J Pharmacol Exp Ther. 2011 Jul;338(1):410.

4.

Influence of genetic background and gender on bladder function in the mouse.

Cornelissen LL, Misajet B, Brooks DP, Hicks A.

Auton Neurosci. 2008 Jun;140(1-2):53-8. doi: 10.1016/j.autneu.2008.04.001. Epub 2008 May 20.

PMID:
18495551
5.

Molecular mechanisms of antidiuretic effect of oxytocin.

Li C, Wang W, Summer SN, Westfall TD, Brooks DP, Falk S, Schrier RW.

J Am Soc Nephrol. 2008 Feb;19(2):225-32. Epub 2007 Dec 5.

6.

The discovery of GSK221149A: a potent and selective oxytocin antagonist.

Liddle J, Allen MJ, Borthwick AD, Brooks DP, Davies DE, Edwards RM, Exall AM, Hamlett C, Irving WR, Mason AM, McCafferty GP, Nerozzi F, Peace S, Philp J, Pollard D, Pullen MA, Shabbir SS, Sollis SL, Westfall TD, Woollard PM, Wu C, Hickey DM.

Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4. Epub 2007 Nov 6.

PMID:
18032036
7.

Carvedilol prevents and reverses hypertrophy-induced cardiac dysfunction.

Barone FC, Willette RN, Nelson AH, Ohlstein EH, Brooks DP, Coatney RW.

Pharmacology. 2007;80(2-3):166-76. Epub 2007 Jun 4.

PMID:
17551266
8.

Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat.

McCafferty GP, Pullen MA, Wu C, Edwards RM, Allen MJ, Woollard PM, Borthwick AD, Liddle J, Hickey DM, Brooks DP, Westfall TD.

Am J Physiol Regul Integr Comp Physiol. 2007 Jul;293(1):R299-305. Epub 2007 Mar 29.

9.

Acetic acid opens large-conductance Ca2+-activated K+ channels in guinea pig detrusor smooth muscle cells.

Ghatta S, Lozinskaya I, Lin Z, Gordon E, Willette RN, Brooks DP, Xu X.

Eur J Pharmacol. 2007 Jun 1;563(1-3):203-8. Epub 2007 Feb 27.

PMID:
17382925
10.

Noninvasive assessment of ectopic uterine tissue development in rats using magnetic resonance imaging.

Lenhard SC, Haimbach RE, Sulpizio AC, Brooks DP, Bray JD, Jucker BM.

Fertil Steril. 2007 Oct;88(4 Suppl):1058-64. Epub 2007 Mar 23.

PMID:
17362941
11.

Antioxidant activity of carvedilol in cardiovascular disease.

Dandona P, Ghanim H, Brooks DP.

J Hypertens. 2007 Apr;25(4):731-41. Review.

PMID:
17351362
12.

Navigating the interview: how to make it work for you.

Klabunde RE, Brooks DP, Korzick DH, Michele D.

Physiologist. 2006 Oct;49(5):260-6. No abstract available.

PMID:
17052044
13.

Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator.

Zeng H, Lozinskaya IM, Lin Z, Willette RN, Brooks DP, Xu X.

J Pharmacol Exp Ther. 2006 Nov;319(2):957-62. Epub 2006 Aug 23.

14.

Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406.

Sulpizio AC, Pullen MA, Edwards RM, Louttit JB, West R, Brooks DP.

J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13. Epub 2005 Sep 6.

15.

Female, but not male, serotonin reuptake transporter (5-HTT) knockout mice exhibit bladder instability.

Cornelissen LL, Brooks DP, Wibberley A.

Auton Neurosci. 2005 Oct 30;122(1-2):107-10. Epub 2005 Jul 14.

PMID:
16023897
16.

Pharmacology of the angiotensin II receptor antagonist, eprosartan.

Edwards RM, Ruffolo RR Jr, Brooks DP.

Expert Opin Investig Drugs. 1998 Mar;7(3):463-9.

PMID:
15991986
17.

Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.

Douglas SA, Behm DJ, Aiyar NV, Naselsky D, Disa J, Brooks DP, Ohlstein EH, Gleason JG, Sarau HM, Foley JJ, Buckley PT, Schmidt DB, Wixted WE, Widdowson K, Riley G, Jin J, Gallagher TF, Schmidt SJ, Ridgers L, Christmann LT, Keenan RM, Knight SD, Dhanak D.

Br J Pharmacol. 2005 Jul;145(5):620-35.

18.

Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.

Grygielko ET, Martin WM, Tweed C, Thornton P, Harling J, Brooks DP, Laping NJ.

J Pharmacol Exp Ther. 2005 Jun;313(3):943-51. Epub 2005 Mar 15.

19.

Okadaic acid stimulates caspase-like activities and induces apoptosis of cultured rat mesangial cells.

Parameswaran N, Spielman WS, Brooks DP, Nambi P.

Mol Cell Biochem. 2004 May;260(1-2):7-11.

PMID:
15228080
20.

Characterization of the neutralizing activity of digoxin-specific Fab toward ouabain-like steroids.

Pullen MA, Brooks DP, Edwards RM.

J Pharmacol Exp Ther. 2004 Jul;310(1):319-25. Epub 2004 Feb 24.

21.

The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.

Sulpizio AC, Pullen MA, Edwards RM, Brooks DP.

J Pharmacol Exp Ther. 2004 Jun;309(3):1141-7. Epub 2004 Feb 9.

23.

Effect of endothelin on bladder contraction: potential role in bladder hyperactivity.

Westfall TD, McCafferty GP, Pullen M, Ventre J, Eybye M, Jugus MJ, Brooks SA, Hieble JP, Brooks DP.

Pharmacology. 2003 Sep;69(1):7-11.

PMID:
12886024
24.

Effects of angiotensins II and IV on blood pressure, renal function, and PAI-1 expression in the heart and kidney of the rat.

Abrahamsen CT, Pullen MA, Schnackenberg CG, Grygielko ET, Edwards RM, Laping NJ, Brooks DP.

Pharmacology. 2002 Sep;66(1):26-30.

PMID:
12169762
25.

The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.

Abrahamsen CT, Barone FC, Campbell WG Jr, Nelson AH, Contino LC, Pullen MA, Grygielko ET, Edwards RM, Laping NJ, Brooks DP.

J Pharmacol Exp Ther. 2002 Apr;301(1):21-8.

26.

Role of caspases in human renal proximal tubular epithelial cell apoptosis.

Wong VY, Keller PM, Nuttall ME, Kikly K, DeWolf WE Jr, Lee D, Ali SM, Nadeau DP, Grygielko ET, Laping NJ, Brooks DP.

Eur J Pharmacol. 2001 Dec 21;433(2-3):135-40.

PMID:
11755144
27.

Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression.

Wong VY, Laping NJ, Nelson AH, Contino LC, Olson BA, Gygielko E, Campbell WG Jr, Barone F, Brooks DP.

Br J Pharmacol. 2001 Nov;134(5):977-84.

28.

Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction.

Behr TM, Nerurkar SS, Nelson AH, Coatney RW, Woods TN, Sulpizio A, Chandra S, Brooks DP, Kumar S, Lee JC, Ohlstein EH, Angermann CE, Adams JL, Sisko J, Sackner-Bernstein JD, Willette RN.

Circulation. 2001 Sep 11;104(11):1292-8.

29.
30.

The role of transforming growth factor-beta and its receptors in human prostate smooth muscle cell fibronectin production.

Butter S, Laping NJ, Pullen M, Grygielko E, Olson B, Brooks DP.

Eur J Pharmacol. 2001 Jun 22;422(1-3):47-52.

PMID:
11430912
31.

Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.

Barone FC, Coatney RW, Chandra S, Sarkar SK, Nelson AH, Contino LC, Brooks DP, Campbell WG Jr, Ohlstein EH, Willette RN.

Cardiovasc Res. 2001 Jun;50(3):525-37.

PMID:
11376628
32.

Parathyroid hormone-1 receptor down-regulation in kidneys from rats with chronic renal failure.

Edwards RM, Contino LC, Gellai M, Brooks DP.

Pharmacology. 2001 May;62(4):243-7.

PMID:
11360002
33.

Rapid isolation of tissue-specific genes from rat kidney.

Hu E, Chen Z, Fredrickson TA, Spurr N, Gentle S, Sims M, Zhu Y, Halsey W, Van Horn S, Mao J, Sathe GM, Brooks DP.

Exp Nephrol. 2001 Mar-Apr;9(2):156-64.

PMID:
11150865
34.

Unmasking of endothelin-1-induced natriuresis and renal vasodilation in the dog by enrasentan (SB 217242).

Brooks DP, DePalma PD.

J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S346-7.

PMID:
11078416
35.

Gene expression in rats with renal disease treated with the angiotensin II receptor antagonist, eprosartan.

Wong VY, Laping NJ, Contino LC, Olson BA, Grygielko E, Brooks DP.

Physiol Genomics. 2000 Nov 9;4(1):35-42.

PMID:
11074011
36.

Desensitization and resensitization of adrenomedullin-sensitive receptor in rat mesangial cells.

Parameswaran N, Aiyar N, Wu H, Brooks DP, Nambi P, Spielman WS.

Eur J Pharmacol. 2000 Nov 3;407(3):205-10.

PMID:
11068015
37.

Renal vasopressin receptor expression and function in rats following spaceflight.

Brooks DP, Nambi P, Laping NJ, Olson BA, Pullen M, Wade CE.

J Appl Physiol (1985). 2000 Apr;88(4):1316-20.

38.

Apoptosis in polycystic kidney disease: involvement of caspases.

Ali SM, Wong VY, Kikly K, Fredrickson TA, Keller PM, DeWolf WE Jr, Lee D, Brooks DP.

Am J Physiol Regul Integr Comp Physiol. 2000 Mar;278(3):R763-9.

39.

Epithelin mRNA expression in polycystic kidney disease.

Ali SM, Nambi P, Fredrickson TA, Brooks DP.

Peptides. 1999 Dec;20(12):1489-95.

PMID:
10698125
40.

Activation of multiple mitogen-activated protein kinases by recombinant calcitonin gene-related peptide receptor.

Parameswaran N, Disa J, Spielman WS, Brooks DP, Nambi P, Aiyar N.

Eur J Pharmacol. 2000 Feb 18;389(2-3):125-30.

PMID:
10688975
41.

Adrenomedullin decreases extracellular signal-regulated kinase activity through an increase in protein phosphatase-2A activity in mesangial cells.

Parameswaran N, Nambi P, Hall CS, Brooks DP, Spielman WS.

Eur J Pharmacol. 2000 Jan 28;388(2):133-8.

PMID:
10666504
42.

Sgk, a putative serine/threonine kinase, is differentially expressed in the kidney of diabetic mice and humans.

Kumar JM, Brooks DP, Olson BA, Laping NJ.

J Am Soc Nephrol. 1999 Dec;10(12):2488-94.

43.

Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data.

Brooks DP, Ohlstein EH, Ruffolo RR Jr.

Am Heart J. 1999 Sep;138(3 Pt 2):246-51. Review.

PMID:
10467220
44.
45.

Effects of eprosartan on glomerular injury in rats with reduced renal mass.

Gandhi M, Meyer TW, Brooks DP.

Pharmacology. 1999 Aug;59(2):89-94.

PMID:
10450063
46.

Regulation of glomerular mesangial cell proliferation in culture by adrenomedullin.

Parameswaran N, Nambi P, Brooks DP, Spielman WS.

Eur J Pharmacol. 1999 May 7;372(1):85-95.

PMID:
10374718
47.

SB203580 reverses adrenomedullin's effect on proliferation and apoptosis in cultured mesangial cells.

Parameswaran N, Spielman WS, Brooks DP, Nambi P.

Eur J Pharmacol. 1999 Apr 23;371(1):75-82.

PMID:
10355597
48.

Mechanism of adrenomedullin-stimulated hyaluronic acid release in rat mesangial cells.

Parameswaran N, Spielman WS, Pullen M, Francis J, Brooks DP, Nambi P.

Eur J Pharmacol. 1999 Apr 16;370(3):313-8.

PMID:
10334508
49.

Cloning and functional characterization of a sodium-dependent phosphate transporter expressed in human lung and small intestine.

Feild JA, Zhang L, Brun KA, Brooks DP, Edwards RM.

Biochem Biophys Res Commun. 1999 May 19;258(3):578-82.

PMID:
10329428
50.

CVT-124, a novel adenosine A1 receptor antagonist with unique diuretic activity.

Gellai M, Schreiner GF, Ruffolo RR Jr, Fletcher T, DeWolf R, Brooks DP.

J Pharmacol Exp Ther. 1998 Sep;286(3):1191-6.

Supplemental Content

Loading ...
Support Center